Ms. Haji is a Senior Program Officer with the market shaping team at Results for Development (R4D) working in the Tanzania country office. As part of the market shaping team, her role is to effectively manage projects focused on improving access to medicines for mothers and children, provide day-to-day thought and technical leadership, lead internal and external stakeholder engagement and support business development efforts for the country office.

Before joining R4D, Nelsha led the strategic and annual business planning processes at the Community Care Access Center in Ontario, Canada – an arm of the Ministry of Health offering home- and community based-services to Ontario residents. As part of her role, she developed and rolled out a standardized annual business planning process and led various business development efforts for the organization. Nelsha also developed and implemented healthcare programs aimed at improving access to care and treatment for non-communicable diseases (NCDs) during her time working for the Aga Khan Hospital in Dar-es-Salaam, Tanzania.

Nelsha holds a master’s degree in business administration with a specialization in health services management and a bachelor of science in nursing from McMaster University.

The post Nelsha Haji appeared first on Results for Development.

Related Resource: Market Report – Amoxicillin Dispersible Tablets Progress and Opportunities

Learn More

WASHINGTON, D.C. — Results for Development (R4D) has published a new report examining progress in increasing access to amoxicillin dispersible tablets (amox DT) — the WHO-recommended treatment for childhood pneumonia. The market report, Amoxicillin Dispersible Tablets Progress and Opportunities, documents progress since 2014 and highlights opportunities to overcome persistent barriers to transform access to this lifesaving commodity.

Childhood pneumonia is the leading killer of children under 5, causing more than 800,000 child deaths per year. To reduce childhood pneumonia deaths, immediate action is needed. This must include increasing access to effective, low-cost and appropriately designed treatments — such as amox DT.

The brief explores aspects of regulatory, financing, supply, demand, and appropriate use of amox DT at the global level and at the national level in countries with high burdens of childhood pneumonia, including [insert country names here]. The brief draws heavily on R4D’s experiences supporting governments in high burden countries, such as Ethiopia, Tanzania and Uganda, to identify and implement efforts to catalytically scale-up amox DT. These findings were also complemented by information produced by key partners

In addition to providing more transparency on the amox DT market, the brief importantly provides recommendations to market actors — including governments, manufacturers and donors — to scale up access to amox DT.

### 

About Results for Development
Results for Development (R4D) is a leading non-profit global development partner. We collaborate with change agents — government officials, civil society leaders and social innovators — supporting them as they navigate complex change processes to achieve large-scale, equitable outcomes in health, education and nutrition. We work with country leaders to diagnose challenges, co-create, innovate and implement solutions built on evidence and diverse stakeholder input, and engage in learning to adapt, iterate and improve. We also strengthen global, regional and country ecosystems to support country leaders with expertise, evidence, and innovations. R4D helps country leaders solve their immediate challenges today, while also strengthening systems and institutions to address tomorrow’s challenges. And we share what we learn so others around the world can achieve results for development too. www.R4D.org  

The post New brief examines challenges, opportunities in increasing access to childhood pneumonia treatment appeared first on Results for Development.

Urgent efforts are needed to scale amoxicillin DT. This market brief aims to document – primarily in qualitative terms – progress seen over the past eight years since the WHO guidance was updated to recommend the use of amoxicillin DT for childhood pneumonia treatment. Importantly, the brief also highlights key remaining opportunities to unlock persistent barriers, and to transform access to this life-saving commodity. Market barriers described in this document focus on aspects of regulatory, financing, supply, demand, and appropriate use of amoxicillin DT at the global level and at the national level in countries with high burdens of childhood pneumonia. The recommendations coming out of this brief provide strong suggestions for where country governments and partners can collectively focus attention in forthcoming years to continue improving access to amoxicillin DT by addressing key enduring challenges:

• Need for prioritization of access to amoxicillin DT in national strategies and investment cases targeting reductions in child mortality;
• Significant funding gaps persist, requiring greater prioritization by both donors and governments;
• Limited availability of internationally quality-assured products – at completive prices – within high-burden countries;
• Need for more robust quantifications and their use to inform procurement decisions; and
• Concerns around appropriate use, supported by evidence of misdiagnosis and incorrect prescription practices

In support of the Sustainable Development Goals to end preventable child mortality, combined and coordinated efforts across partners and governments of high burden countries is greatly needed to prioritize efforts to tackle the barriers documented in this brief, thus enhance scale-up of amoxicillin DT.

The post Market Report – Amoxicillin Dispersible Tablets Progress and Opportunities appeared first on Results for Development.

As program operations officer for Results for Development (R4D), he supports the operational aspects of the market shaping portfolio, including business development, project financing, staffing, contracting compliance, recruitment, communications, and knowledge management. He works with finance, operations, and administrative staff across R4D’s country offices to harmonize project delivery and elevate the internal functioning of the market shaping team.

Prior to joining R4D, Mr. Kimmitt worked at the Palladium Group, where he supported project operations and business development. He worked previously at the Global Health Centre, where he investigated the efficiency of the pharmaceutical development process in commercial and non-commercial contexts. He also worked with the International Committee of the Red Cross, where he was part of the Health Care in Danger project and worked on a cross sectional study evaluating the impact of violence on healthcare in different contexts.

Mr. Kimmitt holds a master’s degree in development studies from the Graduate Institute, Geneva (IHEID). He speaks English, French, and some Wolof.

The post Ryan Kimmitt appeared first on Results for Development.

At Results for Development (R4D), Mr. Khan is a senior program associate on the market shaping practice. He provides technical and programmatic support to the Maternal and Child Wasting (MCW) project, which works to increase access to nutrition commodities and combat malnutrition in Pakistan and Bangladesh.

Prior to R4D, he worked as a health economics and policy consultant at the Health Finance Institute, working to utilize blended finance approaches to addressing the noncommunicable disease gap. Prior to that, he served as a quality management officer at the Malawi Ministry of Health and Population, through Global Health Corps. In that role, he drafted a five-year health facility accreditation roadmap and finalized the quality of pediatric care standards, with the goal of improving the health care quality in Malawi.

Mr. Khan holds a master’s in public health (with a focus on health management) from the Harvard School of Public Health. He also received a BA from Columbia University in Middle Eastern, South Asian, and African Studies. He is a fluent English speaker.

The post Omar Khan appeared first on Results for Development.

At Results for Development (R4D), Ms. Nnachetta is a senior program associate for the market shaping practice. In this role, she analyzes barriers in health product markets and helps in developing strategic solutions to them. She currently supports projects focusing on sexual and reproductive health products, as well as wasting in children and mothers.

Before joining R4D, Ms. Nnachetta worked at FHI 360 supporting the management of large HIV programs for general and key populations across Nigeria. She also supported programming for the COVID-19 emergency response and vaccination efforts in Nigeria, Haiti, Mongolia, Sri Lanka, Maldives, and the Pacific Islands. Prior to that, she was a program assistant in the Office of the Assistant Administrator at USAID’s Global Health Bureau.

Ms. Nnachetta holds a B.S. in biological sciences with a concentration in human nutrition and a minor in global health from Cornell University.

The post Ije Nnachetta appeared first on Results for Development.

As a senior program associate with R4D’s market-shaping practice, Ms. Morgan provides technical and programmatic support to the Maternal, Newborn and Child Health (MNCH) project to increase access to lifesaving MNCH medicines in Sub-Saharan Africa.

Before joining R4D, Ms. Morgan conducted qualitative research in The Gambia for her master’s dissertation and wrote a policy report for the Gambian government on crop diversification as a public health nutrition intervention. Prior to graduate school, she worked as a drug discovery researcher at a biotech start-up, where she contributed to projects on novel therapeutics for cancers and autoimmune diseases.

Ms. Morgan holds an MSc in public health from the London School of Hygiene and Tropical Medicine and a BS in integrative neuroscience with a minor in peace and justice studies from Fordham University.

The post Brighid Morgan appeared first on Results for Development.

At Results at Development (R4D), Mr. Mateshi is a program director in Tanzania where he provides overall strategic leadership and technical direction, leads internal and external partner engagements, and manages high-impact projects and country operations for R4D’s market shaping practice. He also contributes to business development for new opportunities in the portfolio.

In his career, Mr. Mateshi has focused in improving availability of health commodities and uptake of health services. He successfully supported the Tanzania Ministry of Health in the introduction and development of various systems including Implanon NXT, an online HR management system, an online dashboard to improve data analytics and visibility for the family planning program, quantification of RMNCAH, HIV and malaria commodities, strategies and guidelines for RMNCAH and cancer programs and supporting market shaping work for family planning, maternal health, and cancer commodities.

Before joining R4D, Mr. Mateshi was a program manager with the Clinton Health Access Initiative and managed the SRH, cancer, and health financing portfolios in Tanzania.

Mr. Mateshi holds a bachelor’s degree in pharmacy and is completing a master’s degree in health economics and policy from Muhimbili University of Health and Allied Sciences. He is fluent in Swahili and English.

The post Gilbert Mateshi appeared first on Results for Development.